Inhibition of Hepatic Drug Metabolism

Cooper D.Y. , Levin S. , Narasimhulu S. , and Rosenthal O. : Photochemical Action Spectrum of the Terminal Oxidase of Mixed Function Oxidase Systems, Science 147: 400–402, 1965.

Ray J.W. : The Epoxidation of Aldrin by Housefly Microsomes and Its Inhibition by Carbon Monoxide, Biochem. Pharmacol. 16: 99–107, 1967.

Montgomery M.R. , and Rubin R.J. : The Effect of Carbon Monoxide Inhalation on In Vivo Drug Metabolism in the Rat, J. Pharmacol. Exp. Ther. 179: 465–473, 1971.

Cook L. , Toner J.J. , and Fellows E.J. : The Effect of β-Diethylaminoethyldiphenylpropylacetate Hydrochloride (SKF No. 525-A) on Hexobarbital, J. Pharmacol. Exp. Ther. 111: 131–141, 1954.

Axelrod J. , Reichenthal J. , and Brodie B.B. : Mechanism of the Potentiating Action of β-Diethylaminoethyldiphcnylpropylacetate, J. Pharmacol. Exp. Ther. 112: 49–54, 1954.

Gillette J.R. : in Progress in Drug Research Vol. 6., edited by Jucher Ernst . Published by Birkhauser Verlag, Basle und Stuttgart, 1963, p. 49.

Anders M.W. , and Mannering G.J. : Inhibition of Drug Metabolism. I. Kinetics of the Inhibition of the N-demethylation of Ethylmorphine by 2-Diethylaminoethyl 2, 2-diphenylvalerate HCl (SKF 525-A) and related compounds, Mol. Pharmacol. 2: 319–327, 1966.

La Du B.N. , Horning E.C. , Wood H.B. , Trousof N. , and Brodie B.B. : Inhibition of Enzymatic Dealkylation by Compounds Related to β-diethylaminodiphenylpropylacetate (SKF 525-A), Fed. Proc. 13: 377, 1954.

Kato R , and Takayanagi M. : Species Difference in the Inhibition of Drug Metabolism in Liver Microsomes by SKF 525-A, Japan. J. Pharmacol. 16: 127–128, 1966.

Anders M.W. , Alvares A.P. , and Mannering G.J. : Inhibition of Drug Metabolism. II. Metabolism of 2-Diethylaminoethyl 2, 2-diphenylvalerate HCl (SKF 525-A), Mol. Pharmacol. 2: 328–334, 1966.

Cooper J.R. , Axelrod J. , and Brodie B.B. : Inhibitory Effects of β-Diethylaminoethyldiphenylpropylacetate on a Variety of Drug Metabolic Pathways In Vitro, J. Pharmacol. Exp. Ther. 112: 55–63, 1954.

Gillette J.R. , Brodie B.B. , and La Du B.N. : The Oxidation of Drugs by Liver Microsomes: On the Role of TPNH and Oxygen, J. Pharmacol. Exp. Ther. 119: 532–540, 1959.

Schenkman J.B. , Remmer H. , and Estabrook R.W. : Spectral Studies with Hepatic Microsomal Cytochrome, Mol. Pharmacol. 3: 113–123, 1967.

Netter K.J. : in Proceedings of the First International Pharmacological Meeting: Stockholm Vol. VI, published by Pergammon Press, 1962, p. 213–228.

Anders M.W. , and Mannering G.J. : Inhibition of Drug metabolism. IV. Induction of Drug Metabolism by 2-Diethylaminoethyl 2, 2-diphenylvalerate HCl (SKF 525-A) and 2, 4-Dichloro-6-phenylphenoxyethyldiethylamine HBr (Lilly 18947) and the Effect of Induction on the Inhibitory Properties of SKF 525-A Type Compounds, Mol. Pharmacol. 2: 341–346, 1966.

Rogers L.A. , Dixon R.L. , and Fouts J.R. : The Effects of SKF 525-A on Hepatic Glycogen and Rate of Hepatic Drug Metabolism, Biochem. Pharmacol. 12: 341–348, 1963.

Sladek N.E. , and Mannering G.J. : Comparison of Phenobarbital and Methylcholanthrene Induction of Microsomal Enzyme Systems Which N-Demethylate Ethylmorphine and 3-Methyl-4-monomethylaminoazobenzene, Fed. Proc. 25: 418, 1966.

Brodie B.B. : Pathways of Drug Metabolism, J. Pharm. Pharmacol. 8: 1–17, 1956.

Gaudette L.E. , and Brodie B.B. : Relationship Between the Lipid Solubility of Drugs and Their Oxidation by Liver Microsomes, Biochem. Pharmacol. 2: 89–96, 1959.

Gillette J.R. , and Kamm J.J. : The Enzymatic Formation of Sulphoxides: The Oxidation of Chlorpromazine and 4, 4-Diamino-Diphenyl Sulphide by Guinea Pig Liver Microsomes, Pharmacol. Exp. Ther. 130: 262–267, 1960.

Fouts J.R. , and Brodie B.B. : On the Mechanism of Drug Potentiation by Iproniazid, J. Pharmacol. Exp. Ther. 116: 480–485, 1956.

London D.R. , and Milne M.D. : Dangers of Monoamine Oxidase Inhibitors, Brit. Med. J. 2: 1752, 1962.

Laroche M.J. , and Brodie B.B. : Lack of Relationship Between Inihibition of Monoamine Oxidase and Potentiation of Hexobarbital Hypnosis, J. Pharmacol. Exp. Ther. 130: 134–137, 1960.

Clarke B. : The In Vitro Inhibition of the N-Demethylation of Pethidine by Phenelzine (Phenethylhydrazine), Biochem. Pharmacol. 16: 2369–2385, 1967.

Eade N.R. , and Renton K.W. : Effect of Monoamine Oxidase Inhibitors on the N-Demethylation and Hydrolysis of Meperidine, Biochem. Pharmacol. 19: 2243–2250, 1970.

Rogers K.J. , and Thornton J.A. : The Interaction Between Monamine Oxidase Inhibitors and Narcotic Analgesics in Mice, Brit. J. Pharmacol. 36: 470–480, 1969.

Price Evans D.A. , Davison K. , and Pratt R.T.C. : The Influence of Acetylator Phenotype on the Effects of Treating Depression with Phenelzine, Clin. Pharmacol. Ther. 6: 430–435, 1965.

Leibman K.C. : Effects of Metyrapone on Liver Microsomal Drug Oxidations, Fed. Proc. 25: 417, 1966.

Leibman K.C. : Effects of Metyrapone on Liver Microsomal Drug Oxidations, Mol. Pharmacol. 5: 1–9, 1969.

Netter K.J. , Kahl G.F. , and Magnussen M.P. : Kinetic Experiments on the Binding of Metyrapone to Liver Microsomes, Nauyn-Schmiedebergs Arch. Pharmak. 265: 205–215, 1969.

Tephly T.R. , and Mannering G.J. : Inhibition of Drug Metabolism V. Inhibition of Drug Metabolism by Steroids, Mol. Pharmacol. 4: 10–14, 1968.

Dixon R.L. , and Fouts J.R. : Inhibition of Microsomal Drug Metabolic Pathways by Chloramphenicol, Biochem. Pharmacol. 11: 715–720, 1962.

Dixon R.L. : Effect of Chloramphenicol on the Metabolism and Lethality of Cyclophosphamide in Rats, Proc. Soc. Exp. Biol. Med., 127: 1151–1155, 1968.

Hart L.G. , and Adamson R.H. : Effect of Microsomal Enzyme Modifiers on Toxicity and Therapeutic Activity of Cyclophosphamide in Mice, Arch. Int. Pharmacodyn, 180: 391–401, 1969.

Dubois K.P. : Inhibition by Radiation of the Development of Drug Detoxification Enzymes, Radiat. Res. 30: 342–350, 1967.

Heitbrink B.E. , and Dubois K.P. : Influence of Partial Body X-Irradiation on Development of Phosphorothioate Oxidase in the Livers of Male Rats, Radiat. Res. 27: 669–675, 1966.

Tardiff R.G. , and Dubois K.P. : Inhibition of Hepatic Microsomal Enzymes by Alkylating Agents, Arch. Int. Pharmacodyn, 177: 445–456, 1969.

Christenen L.K. , Hansen J.M. , and Kristensen M. : Sulphaphenazole-Induced Hypoglycaemic Attacks in Tolbutamide-Treated Diabetics, Lancet 2: 1298–1301, 1963.

Christensen L.K. , and Skovsted L. : Inhibition of Drug Metabolism by Chloramphenicol, Lancet 2: 1397–1399, 1969.

Ballek R.E. , Reindenberg M.M. , and Orr L. : (Letter) Inhibition of Diphenylhydantoin Metabolism by Chloramphenicol, Lancet 1: 150, 1973.

Brotherton P.M. , Grieveson P. , and McMartin C. : A Study of the Metabolic Fate of Chlorpropamide in Man, Clin. Pharmacol. Ther. 10: 505–514, 1969.

Petitpierre B. , and Fabre J. : (Letter) Chlorpropamide and Chloramphenicol, Lancet 1: 789, 1970.

Solomon H.M. , and Schrogie J.J. : Effect of Phenyramidol and Bishydroxycoumarin on the Metabolism of Tolbutamide in Human Subjects, Metabolism 16: 1029–1033 1967.

Kristensen K. , and Hansen J.M. : Potentiation of the Tolbutamide Effect by Dicoumarol, Diabetes 16: 211–214, 1967.

Vessell E.S. , Passananti G.T. , and Greene F.E. : Impairment of Drug Metabolism in Man by Allopurinol and Nortriptyline, N. E. J. Med. 283: 1484–1488, 1970.

Garretson L.K. , Perel J.M. , and Dayton P.G. : Methylphenidate Interaction with Both Anticonvulsants and Ethyl Biscoumacetate, J. Amer. Med. Assoc. 207: 2053–2056, 1969.